Asia/Oceania

ImmunoScape Raises $14M

Biocytogen Pharmaceuticals, Guangzhou FineImmune Biotechnology Ink Cell Therapy Partnership

FDA Clears Anbogen Therapeutics to Study ABT-101 in HER2-Mutant NSCLC Patients in the US

METiS Gets Exclusive License to Voronoi's Pan-RAF Inhibitor

Head and Neck Cancer Treatment Targets, Biomarkers Unearthed in Cell Model Analyses

Ideaya Begins Phase I Trial of Darovasertib in Primary Uveal Melanoma

Jacobio Pharma Doses First NSCLC Patient in JAB-21822 Trial in China

Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients

RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer

Genome Insight, Ajou University Medical Center to Test WGS Use for Routine Cancer Care

Avelos Closes $8 Million Series A Financing to Develop Synthetic Lethality Pipeline

Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan

In Brief This Week: Immatics, Aktis Oncology, Daiichi Sankyo, Roche Pharma India, Genetron

AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan

Oncgnostics Epigenetic Cervical Cancer Test Wins Chinese Regulatory Approval

Innovative Cellular Therapies Begins Trial of Autologous CAR T-Cell Therapy in Colorectal Cancer

Tessa Therapeutics Starts Trial of CAR T-Cell Therapy, BMS's Opdivo in Classical Hodgkin Lymphoma

Gilead Sciences Files for Trodelvy FDA Approval in HR-Positive Breast Cancer, Buys Rights in Asia

Immuno-Genomic Features Predict Treatment Response in Esophageal Carcinoma